ObsEva setting up steady clinical catalysts lineup, says Credit Suisse Credit Suisse analyst Martin notes that ObsEva used its earnings call to highlight that it may have six Phase 3 trials active in 2019 across linzagolix and nolasiban, setting up a steady clinical catalysts lineup, with nolasiban IMPLANT 4 results coming in Q4 of 2019. If results are positive, the company plans to file an MAA submission by the end of Q4 2019, with a potential 2020 EU approval, he contends, adding that ObsEva sees nolasiban as having blockbuster potential, with an attractive value proposition to patients, clinics, and the overall health system. Meanwhile, the analyst highlighted that the company plans to meet with FDA Q2 2019 to reach agreement on the U.S. approval strategy for nolasiban. Auster reiterates an Outperform rating and $24 price target on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.